I'm LongbridgeAI, I can summarize articles.Imugene Limited has applied to the ASX for the quotation of 17,829 new ordinary shares, set to be issued on January 11, 2026, following the conversion of existing options. This increase in quoted securities is part of routine capital management and will not significantly impact ownership or operations. The additional shares will rank as ordinary equity alongside existing IMU securities. The latest analyst rating for Imugene stock is a Hold with a price target of A$0.14. Imugene focuses on developing novel immunotherapies in the biotechnology sector.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) has issued an announcement.
Imugene Limited has applied to the ASX for quotation of 17,829 new ordinary fully paid shares, to be issued on 11 January 2026 following the conversion or exercise of existing options or other convertible securities. The modest increase in quoted securities slightly expands Imugene’s share capital base and reflects routine capital management activity, with limited immediate impact on ownership structure or day-to-day operations.
The application, lodged as a new announcement under Appendix 2A of the ASX Listing Rules, confirms that the additional shares will rank as ordinary equity alongside existing IMU securities. While small in scale, such incremental issuances are part of the company’s broader approach to funding and incentivising stakeholders within the competitive biotechnology market.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australia-listed biotechnology company focused on developing novel immunotherapies, with its ordinary fully paid shares traded on the ASX under the code IMU. The company operates in the biopharmaceutical sector, where equity issuances and option exercises are common tools to support ongoing research, development, and corporate activities.
Average Trading Volume: 1,646,802
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$51.77M